Last reviewed · How we verify
ALATROFLOXACIN
Alatrofloxacin is a small molecule antibiotic developed by Pfizer, which is currently owned by the same company. It was approved by the FDA in 1997 for various bacterial infections, including those caused by Moraxella catarrhalis, Klebsiella pneumoniae, and Chlamydia. Alatrofloxacin is off-patent and has no active Orange Book patents, indicating that it is available as a generic medication. However, there are currently no generic manufacturers listed. As an off-patent medication, its commercial status is subject to change.
At a glance
| Generic name | ALATROFLOXACIN |
|---|---|
| Sponsor | Pfizer |
| Drug class | alatrofloxacin |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1997 |
Approved indications
- Acute Moraxella catarrhalis bronchitis
- Acute bacterial bronchitis
- Acute bacterial sinusitis
- Acute gonococcal cervicitis
- Acute gonococcal endometritis
- Acute gonococcal urethritis
- Bacterial infection due to Klebsiella pneumoniae
- Chlamydia Cervicitis
- Chlamydial pelvic inflammatory disease
- Chlamydial pneumonia
- Chronic Bacterial Prostatitis
- Colorectal Surgery Infection Prevention
- Female genital tract infection
- Gonorrhea of rectum
- Haemophilus Influenzae Bronchitis
- Haemophilus Parainfluenzae Bronchitis
- Haemophilus influenzae pneumonia
- Infection of skin AND/OR subcutaneous tissue
- Infectious disease of abdomen
- Legionella Pneumophila Pneumonia
Common side effects
Drug interactions
- mesoridazine
- thioridazine
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALATROFLOXACIN CI brief — competitive landscape report
- ALATROFLOXACIN updates RSS · CI watch RSS
- Pfizer portfolio CI